RenovoRx Appoints Mark Voll as Chief Financial Officer for Commercial Growth

Friday, Feb 6, 2026 7:03 am ET1min read
RNXT--

RenovoRx has appointed Mark Voll as Chief Financial Officer, effective February 1, 2026. Voll brings over three decades of financial leadership experience, with a strong track record in guiding high-growth public companies through commercial buildout and strategic development. He joins RenovoRx to support the company's commercial growth of RenovoCath, a patented, FDA-cleared drug-delivery device. Voll's appointment strengthens RenovoRx's C-suite leadership and positions the company for future growth.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet